Exactech, a developer and producer of bone and joint restoration products, announced that is has sold its dental biologic assets to Salvin Dental Specialities.
Exactech sold "substantially all the assets of its dental biologics business" to Salvin through its Salvin Regenerative subsidiary. Salvin is a privately held company that develops, manufactures, and markets regenerative biomaterials and surgical instrumentation for implant dentistry. Salvin will acquire Exactech's dental biologic products, including Optecure, an engineered bone graft, and Oralife.
"While it has been a pleasure to provide Exactech's biologic innovations to the dental market for more than 10 years, we have made the strategic decision to focus more exclusively on our core orthopedic business," stated Bruce Thompson, senior vice president and general manager of spine and biologics of Exactech, in a press release. "We have enjoyed a long-standing distribution relationship with Salvin, which gives us confidence that they will take good care of our dental customers in their pursuit of improving patient care."
Financial terms of the agreement were not disclosed.
